Log In
Print
BCIQ
Print
Print this Print this
 

Tradjenta, Trajenta, Trazenta, linagliptin

Also known as: BI 1356

  Manage Alerts
Collapse Summary General Information
Company Boehringer Ingelheim GmbH
DescriptionXanthine-based dipeptidyl peptidase-4 (DPP-4) inhibitor
Molecular Target Dipeptidyl peptidase-4 (DPP-4) (CD26)
Mechanism of ActionDipeptidyl peptidase-4 (DPP-4) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationDiabetes
Indication DetailsTreat diabetic nephropathy in Type II diabetics; Treat Type II diabetes; Treat Type II diabetes as add-on therapy to insulin; Treat Type II diabetes in patients with albuminuria
Regulatory Designation
Partner Eli Lilly and Co.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$2,367.9M

$386.0M

$1,456.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today